Development and analysis of a multi-node dynamic model for the simulation of stratified thermal energy storage

To overcome non-programmability issues that limit the market penetration of renewable energies, the use of thermal energy storage has become more and more significant in several applications where there is a need for decoupling between energy supply and demand. The aim of this paper is to present a multi-node physics-based model for the simulation of stratified thermal energy storage, which allows the required level of detail in temperature vertical distribution to be varied simply by choosing the number of nodes and their relative dimensions. Thanks to the chosen causality structure, this model can be implemented into a library of components for the dynamic simulation of smart energy systems. Hence, unlike most of the solutions proposed in the literature, thermal energy storage can be considered not only as a stand-alone component, but also as an important part of a more complex system. Moreover, the model behavior has been analyzed with reference to the experimental results from the literature. The results make it possible to conclude that the model is able to accurately predict the temperature distribution within a stratified storage tank typically used in a district heating network with limitations when dealing with small storage volumes and high flow rates

Fire damage assessment in Sardinia: the use of ALOS/PALSAR data for the management of post-fire effects

Fires in the Sardinia Island are one of the most important environmental factors controlling the ecosystem´s function and structure. The evaluation of fire effects by means of remote sensing is economically and practically the best way to assess fire damage, before going to the field. The use of alternative techniques for fire effects assessment is needed, in particular to characterize the biomass loss at the regional level. Radar remotely sensed data can provide great advantages with respect to optical sensors. The paper is devoted to show the results obtained by applying a semi-automatic algorithm to the images of the L-band SAR sensor PALSAR, on board of the ALOS satellite, for the estimate of the burned area. To assess the quality of the estimate, the radar based results have been compared with those obtained from optical data and ground based information

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study

D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE) for the risk of recurrence. However, this approach was never evaluated since direct oral anticoagulants are available. With this multicenter, prospective cohort study, we aimed to assess the value of an algorithm incorporating serial D-dimer testing and administration of reduced-dose apixaban (2.5 mg twice daily) only to patients with a positive test. A total of 732 outpatients aged 18 to 74 years, anticoagulated for ≥12 months after a first unprovoked VTE, were included. Patients underwent D-dimer testing with commercial assays and preestablished cutoffs. If the baseline D-dimer during anticoagulation was negative, anticoagulation was stopped and testing repeated after 15, 30, and 60 days. Patients with serially negative results (286 [39.1%]) were left without anticoagulation. At the first positive result, the remaining 446 patients (60.9%) were given apixaban for 18 months. All patients underwent follow-up planned for 18 months. The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval [CI], 4.5-11.2), including symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) recurrence, death for VTE, and major bleeding occurring in patients off anticoagulation vs that in those receiving apixaban (1.1%; 95% CI, 0.4-2.6; adjusted hazard ratio [HR], 8.2; 95% CI, 3.2-25.3). In conclusion, in patients anticoagulated for ≥1 year after a first unprovoked VTE, the decision to further extend anticoagulation should not be based on D-dimer testing. The results confirmed the high efficacy and safety of reduced-dose apixaban against recurrences. This trial was registered at www.clinicaltrials.gov as #NCT03678506